Fosun Pharma's Small Molecule Innovative Drug XH-S004 Achieves Overseas Licensing for a Potential Total of $645 Million
SHANGHAI, Aug. 11, 2025 /PRNewswire/ -- On August 11, Fosun Pharma (SSE:600196, HKEX: 02196) announced that its subsidiary Fosun Pharma Industrial has signed a License Agreement with Expedition The...
How does this licensing deal influence Fosun Pharma's strategic positioning in the global small‑molecule innovative drug market?
What is the expected impact on Fosun Pharma's stock price volatility and analyst sentiment following this announcement?
What accounting treatment will be applied for the licensing revenue under IFRS/US GAAP, and how will it affect the company's financial statements?
15 days ago